{"disease":{"id":"duodenal-ulcer","name":"duodenal ulcer"},"drugs":{"marketed":[{"drug_id":"omeprazole","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"omeprazole","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"nizatidine","indication_name":"Maintenance Therapy for Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"dexrabeprazole","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"dexrabeprazole","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"amoxycillin","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"carafate","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carafate","generic_name":"Carafate","company_name":"Forest Labs Inc","drug_phase":"marketed","molecular_target":"Pepsin A-5","drug_class":"Aluminum Complex [EPC]","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"carafate","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carafate","generic_name":"Carafate","company_name":"Forest Labs Inc","drug_phase":"marketed","molecular_target":"Pepsin A-5","drug_class":"Aluminum Complex [EPC]","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"bismuth-subsalicylate","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepto-Bismol","generic_name":"bismuth subsalicylate","company_name":"Generic (Procter & Gamble)","drug_phase":"marketed","molecular_target":"Cyclooxygenase","drug_class":"Bismuth [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"sucralfate","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carafate","generic_name":"sucralfate","company_name":"Generic (originally Marion Merrell Dow)","drug_phase":"marketed","molecular_target":"Pepsin A-5","drug_class":"Aluminum Complex [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"sucralfate","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carafate","generic_name":"sucralfate","company_name":"Generic (originally Marion Merrell Dow)","drug_phase":"marketed","molecular_target":"Pepsin A-5","drug_class":"Aluminum Complex [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ranitidine","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ranitidine","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"amoxicillin","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"famotidine","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepcid","generic_name":"famotidine","company_name":"Generic (originally Yamanouchi/Merck)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion."},{"drug_id":"famotidine","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepcid","generic_name":"famotidine","company_name":"Generic (originally Yamanouchi/Merck)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion."},{"drug_id":"algeldrate","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"ALGELDRATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"algeldrate","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"prevacid","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prevacid","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prevacid","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"esomeprazole","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexium","generic_name":"esomeprazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton pump inhibitor (PPI)","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"revaprazan","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revanex","generic_name":"REVAPRAZAN","company_name":"","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"revaprazan","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"aluminum-carbonate","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aluminum carbonate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"aluminum carbonate","quality_score":null,"revenue":null,"mechanism":"Aluminum carbonate works by neutralizing stomach acid and forming a protective barrier over the stomach lining."},{"drug_id":"aciphex","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"aciphex","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aciphex","company_name":"University of Utah","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"cimetidine","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagamet","generic_name":"CIMETIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"cimetidine","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagamet","generic_name":"CIMETIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"bismuth-subcitrate","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pylera","generic_name":"BISMUTH SUBCITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"rabeprazole","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aciphex","generic_name":"rabeprazole","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"Proton Pump Inhibitor","quality_score":80,"revenue":null,"mechanism":"Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"nizatidine","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"nizatidine","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"clarithromycin","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"takecab","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Takecab","company_name":"Genuine Research Center, Egypt","drug_phase":"phase_1","molecular_target":"Potassium-transporting ATPase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rabeprazol","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"rabeprazol","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rabeprazol","company_name":"Janssen-Cilag, S.A.","drug_phase":"discontinued","molecular_target":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"metronidazol","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"omeprazol","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"omeprazol","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lansoprazole","indication_name":"Duodenal Ulcer due to H. Pylori","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"lansoprazole","indication_name":"Duodenal ulcer disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"chembl-chembl1219","indication_name":"Healing of Duodenal Ulcers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RABEPRAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"lansoprazole","indication_name":"Maintenance of Healing Duodenal Ulcer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"nizatidine","indication_name":"Active Duodenal Ulcer Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axid Ar","generic_name":"NIZATIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":46,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03214952","title":"Drug Use Surveillance of Vonoprazan for \"Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis\"","phase":"","overall_status":"COMPLETED","enrollment_count":3183,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01729182","title":"Nexium Capsules LDA Specific Clinical Experience Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":2363,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01562600","title":"Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":1634,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02423187","title":"Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin","phase":"","overall_status":"COMPLETED","enrollment_count":1568,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT03214198","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use\"","phase":"","overall_status":"COMPLETED","enrollment_count":1304,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03214094","title":"Special Drug Use Surveillance of Vonoprazan for \"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use\"","phase":"","overall_status":"COMPLETED","enrollment_count":1119,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05208268","title":"A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer","phase":"","overall_status":"COMPLETED","enrollment_count":676,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT03219723","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","phase":"","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03050359","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":533,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06815822","title":"Prevention of Postoperative Hernias in Emergency Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Jan Kochanowski University","has_results":false},{"nct_id":"NCT04215653","title":"A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":448,"lead_sponsor_name":"Sihuan Pharmaceutical Holdings Group Ltd.","has_results":false},{"nct_id":"NCT05010954","title":"Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","has_results":false},{"nct_id":"NCT04702542","title":"To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan","has_results":false},{"nct_id":"NCT03342456","title":"The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"The Third Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04503629","title":"A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Sihuan Pharmaceutical Holdings Group Ltd.","has_results":false},{"nct_id":"NCT06393907","title":"Hemostatic Forceps vs. Bipolar Electrocautery Probes for High-Risk Bleeding Gastroduodenal Ulcers","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT04994184","title":"Scoring System in Predicting Perforated Duodenal Ulcer Morbidity and Mortality in Bpkihs","phase":"","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"B.P. Koirala Institute of Health Sciences","has_results":false},{"nct_id":"NCT04716166","title":"Incentive Spirometry and Upper Abdominal Laparoscopic Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Riphah International University","has_results":false},{"nct_id":"NCT03553563","title":"A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06098742","title":"Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Valenta Pharm JSC","has_results":false},{"nct_id":"NCT02175186","title":"Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Young-Hak Kim, MD, PhD","has_results":false},{"nct_id":"NCT05959486","title":"A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of \"BR6002\" and Coadministration of \"BR6002A\" and \"BR6002B\" Under Fasting Conditions in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06552624","title":"Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Valenta Pharm JSC","has_results":false},{"nct_id":"NCT05959499","title":"A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of \"BR6002\" and Coadministration of \"BR6002A\" and \"BR6002B\" Under Fed Conditions in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04431037","title":"Early Oral Feeding vs Traditional Post-operative Care In Emergency Abdominal Surgeries","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"College of Physicians and Surgeons Pakistan","has_results":false},{"nct_id":"NCT04123899","title":"BE Study of Gaster®D Tab 20mg (Manufacturer Changed)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Dong-A ST Co., Ltd.","has_results":false},{"nct_id":"NCT06165237","title":"A Study to Evaluate the Drug-drug Interaction and Safety Between \"BR6001-1\" and \"BR6001-2\"","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT05579444","title":"Systems Biology of Gastrointestinal and Related Diseases","phase":"","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Viome","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}